Imcyse is a clinical-stage biotech company headquartered in Liège, Belgium, created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Numerous proof of concept studies have been completed in animal models for type 1 diabetes, multiple sclerosis, myasthenia gravis, allergic diseases, prevention of graft rejection and blocking of immunogenicity to viral vectors. Imcyse’s technology and results are protected by a robust, international intellectual property portfolio.

Type 1 diabetes project is currently in clinical evaluation in patients.